Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404170 · ClinicalTrials.gov registry record · Phase 2
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
A Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
NCT00404170: Completed Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
NCT00404170 is a Phase 2 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 396 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00404170, a Phase 2 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in the PRECEPT cohort, an already existing cohort of 806 subjects recruited to participate in the study called, A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Early Parkinson's Disease - (PRECEPT), sponsored by Cephalon and Lundbeck and coordinated by the Parkinson Study Group. The imaging data from this long-term PRECEPT follow-up study will allow us to evaluate the long-term progression of DAT loss in PD, the long-term follow-up of SWEDD subjects, the relationship between long-term clinical and imaging PD outcomes, and the relationship between long-term imaging outcomes and genetic and biochemical biomarkers of PD progression.
Interventions
- DRUG B-CIT and SPECT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2006-11 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
What the finished NCT00404170 record still lists
NCT00404170 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher).
The record links to 0 conditions, and to 1 intervention - of which B-CIT and SPECT imaging is the first listed.
NCT00404170 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00404170 about?
NCT00404170 is a clinical study titled "Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease". The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in the PRECEPT cohort, an already existing cohort of 806 subjects recruited to participate in the study called, A Ra...
What is the current status of trial NCT00404170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2006-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00404170?
The interventions under investigation include: B-CIT and SPECT imaging (DRUG).
Who is sponsoring clinical trial NCT00404170?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00404170's enrollment target sits among peer trials
396 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia